Trial Information

A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient

This study was a multi-center, open, randomized-control study. It evaluates the effects and
safety of idarubicin 60mg/M2 combined with BUCY pretreatment program or BUCY pretreatment
program on acute myeloid leukemia patient in high-risk group. 200 patients were studied with
100 patients in each group.

Patients enrolled were randomly divided into group A (idarubicin 60mg/M2 combined with BUCY
group) and group B (BUCY group). SAS randomization software was used to obtain randomization
numbers. Patients were recommend to start pretreatment within 7 days after randomization.

Main objective: 2-year overall survival (OS) and disease-free survival (DFS) rates.

Secondary objective: safety evaluation (early complications of transplantation, liver,
kidney and heart toxicity, treatment-related mortality, blood recovery time), the median
period of disease-free survival.

Test drugs Idarubicin (Zavedos ®, Pfizer), busulfan, cyclophosphamide.

Pretreatment plan Drug Group A (IDA 60mg/M2 + BUCY) Group B (BUCY) IDA: 20mg/m2 a day, d-12
~d-10, intravenous infusion for 1 hour. BU: 4mg/Kg a day, oral administration, d-7 ~d-4, or
3.2mg/Kg a day, intravenous infusion, d-7~d-4.

CY: 60mg/Kg a day, intravenous infusion, d-3~d-2. GVHD prevention plan GVHD is prevented by
CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day
-1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function
returned normal when method of administration was changed to oral administration. 5mg/kg was
divided into twice oral intakes, maintaining cyclosporine concentration at 200-300ug / L;
MTX 15mg/m2 at day +1, 10mg/m2 at day +3, +6 and day +11 (based on actual situations day 11
can be omitted); MMF 0.25g BID starting from day 0 and continued for a month ). Unrelated
allogeneic hematopoietic stem cell transplantation used CSA MMF MTX ATG for the prevention
of GVHD. 3mg/kg CSA was infused through continuous intravenous drip since day -1 until
gastrointestinal function returned to normal when the administration method was changed to
oral. 5mg/kg was divided to twice oral intakes maintaining cyclosporine concentrations at
200-300ug/L; MTX 15mg/m2, at day +1, 10mg/m2 at day +3, day +6 and day +11 (based on actual
situations day 11 can be omitted); MMF 0.5g BID starting from day 0 and continued for 3
months (a month later, dose can be reduced according to the hemogram); the total ATG was
6mg/kg and was taken in three days, from day -4 to day -2.

Relapse intervention Routine preventive DLI is not recommended, however, if tendency of
recurrence found during monitor, chemotherapy, immunotherapy, targeted therapy, secondary
transplantation, etc. can be used, and intervention treatment start time should be recorded
as the end time.

The efficacy evaluation time point

1. 1-3, 6, 12, 18, 24 months after transplantation.

2. Follow-up evaluation: indicators such as blood routines and bone marrow detection, and
minimal residual disease detection after the end of treatment should be done regularly.